Various pharmaceutical companies conduct clinical trials for the development of new effective treatments for various skin conditions. Dr Kim completed his Master of Medicine from the University of Sydney through a clinical trial on vitamin D, and has been involved in a number of other clinical trials.
Cornerstone Dermatology has special interest in clinical trials. Please enquire about ongoing clinical trials the clinic is currently involved in.
Currently recruiting Clinical Trials
Atopic Dermatitis (Eczema)
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis – Click here
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis – Click here
Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata – Click here
Plaque Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis – Click here
For expressions of interest to participant in a clinical trial, please contact our Clinical Trials Team on:
Phone: (07) 3397 3200
Fax: (07) 3397 3900
Email: trials@cornerstonederm.com.au
Principal Investigator:
- Dr Young Jin Kim
Sub Investigator:
- Dr Shiva Baghaei
Clinical Nurse Specialist/Nurse Researcher:
- Teagan Holland
- Margaret Anders
Upcoming Clinical Trials
Chronic Spontaneous Urticaria (CSU)
Adolescent Obesity
Vitiligo
Successful Trial Medications
Our Clinical Trial team has worked with the following medications which are now approved for use in Australia for the following conditions:
Atopic Dermatitis (Eczema)
- Dupilumab (Dupixent)
- Upadacitinib (Rinvoq)
Hidradenitis Suppurativa (HS)
- Adalimumab (Humira)
Psoriasis
- Ixekizumab (Taltz)
- Apremilast (Otezla)
- Adalimumab (Humira)
- Secukinumab (Cosentyx)
- Guselkumab (Tremfya)
- Tildrakizumab (Ilumya)
- Risankizumab (Skyrizi)
- Deucravacitinib (Sotyktu)
Chronic Spontaneous Urticaria (CSU)
- Omalizumab (Xolair)
